COL4A5_HUMAN,G609A,0.897,Loss of B-factor (Pr = 0.28 | P = 0.02), None,-
COL4A5_HUMAN,G1164A,0.921,Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.7e-03); Gain of Acetylation at K1166 (Pr = 0.22 | P = 0.03); Gain of SUMOylation at K1166 (Pr = 0.21 | P = 0.03), None,-
COL4A5_HUMAN,G533E,0.937,, None,-
COL4A5_HUMAN,G204D,0.955,Gain of Loop (Pr = 0.33 | P = 1.3e-03); Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G805E,0.928,Gain of Loop (Pr = 0.28 | P = 0.02); Altered Metal binding (Pr = 0.12 | P = 0.03), None,-
COL4A5_HUMAN,G669R,0.930,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K664 (Pr = 0.27 | P = 7.1e-03); Loss of Methylation at K664 (Pr = 0.14 | P = 0.02), ELME000006,-
COL4A5_HUMAN,G1255R,0.951,Loss of Loop (Pr = 0.32 | P = 3.4e-03); Loss of B-factor (Pr = 0.30 | P = 8.9e-03); Loss of Methylation at K1251 (Pr = 0.27 | P = 1.2e-03); Gain of Acetylation at K1251 (Pr = 0.24 | P = 0.02); Gain of SUMOylation at K1251 (Pr = 0.23 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G1241D,0.915,Gain of Loop (Pr = 0.32 | P = 2.0e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of O-linked glycosylation at S1242 (Pr = 0.16 | P = 0.03), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1241V,0.910,Loss of B-factor (Pr = 0.37 | P = 4.9e-04); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of O-linked glycosylation at S1242 (Pr = 0.20 | P = 0.02), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,P739S,0.196,-,-,-
COL4A5_HUMAN,G420R,0.863,Altered Disordered interface (Pr = 0.32 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of O-linked glycosylation at S417 (Pr = 0.14 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G174R,0.961,Altered Disordered interface (Pr = 0.28 | P = 0.03); Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K170 (Pr = 0.20 | P = 6.0e-03); Loss of Sulfation at Y175 (Pr = 0.02 | P = 0.03), ELME000005|ELME000095|ELME000122|ELME000155,-
COL4A5_HUMAN,G1089E,0.940,Gain of Sulfation at Y1090 (Pr = 0.02 | P = 0.03), None,-
COL4A5_HUMAN,G696D,0.947,Gain of Loop (Pr = 0.30 | P = 4.4e-03); Loss of SUMOylation at K698 (Pr = 0.25 | P = 9.4e-03); Gain of Acetylation at K698 (Pr = 0.19 | P = 0.05); Loss of Methylation at K698 (Pr = 0.18 | P = 9.6e-03), ELME000064|PS00008,-
COL4A5_HUMAN,G878V,0.947,Loss of B-factor (Pr = 0.32 | P = 3.7e-03), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1066V,0.942,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Gain of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K1065 (Pr = 0.20 | P = 0.03); Loss of Methylation at K1062 (Pr = 0.19 | P = 7.4e-03); Gain of O-linked glycosylation at S1071 (Pr = 0.13 | P = 0.04), None,-
COL4A5_HUMAN,G772S,0.920,Gain of Phosphorylation at G772 (Pr = 0.36 | P = 8.6e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K768 (Pr = 0.18 | P = 0.05); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000136|ELME000146|ELME000159|PS00005,-
COL4A5_HUMAN,G1015E,0.943,Altered Disordered interface (Pr = 0.30 | P = 0.02), ELME000149,-
COL4A5_HUMAN,G1182R,0.961,Loss of Loop (Pr = 0.30 | P = 6.1e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of SUMOylation at K1181 (Pr = 0.26 | P = 5.9e-03); Gain of Acetylation at K1181 (Pr = 0.21 | P = 0.04); Loss of Methylation at K1181 (Pr = 0.20 | P = 7.2e-03), ELME000005|ELME000100|ELME000108|ELME000155,-
COL4A5_HUMAN,G54D,0.960,Gain of Loop (Pr = 0.29 | P = 7.2e-03), None,-
COL4A5_HUMAN,F222C,0.842,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K226 (Pr = 0.24 | P = 0.02); Loss of Methylation at K226 (Pr = 0.19 | P = 8.3e-03), None,-
COL4A5_HUMAN,G852V,0.911,Loss of B-factor (Pr = 0.32 | P = 5.0e-03); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G189V,0.942,Gain of O-linked glycosylation at T188 (Pr = 0.33 | P = 4.2e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03), None,-
COL4A5_HUMAN,G609R,0.944,Loss of Loop (Pr = 0.32 | P = 4.1e-03); Loss of B-factor (Pr = 0.28 | P = 0.02), None,-
COL4A5_HUMAN,G621V,0.915,Altered Disordered interface (Pr = 0.31 | P = 0.02); Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G1170S,0.952,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.6e-03); Loss of Acetylation at K1166 (Pr = 0.21 | P = 0.04); Loss of SUMOylation at K1166 (Pr = 0.20 | P = 0.03), ELME000202,-
COL4A5_HUMAN,G1018D,0.941,Altered Disordered interface (Pr = 0.28 | P = 0.04); Loss of Loop (Pr = 0.26 | P = 0.05), None,-
COL4A5_HUMAN,K748N,0.608,Gain of Loop (Pr = 0.29 | P = 8.4e-03); Loss of Methylation at K748 (Pr = 0.25 | P = 1.9e-03); Loss of Acetylation at K748 (Pr = 0.24 | P = 0.02); Loss of SUMOylation at K748 (Pr = 0.18 | P = 0.05), ELME000002,-
COL4A5_HUMAN,G1083D,0.945,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K1082 (Pr = 0.23 | P = 3.5e-03), ELME000002|ELME000005|ELME000155,-
COL4A5_HUMAN,G828E,0.939,Gain of Loop (Pr = 0.35 | P = 5.7e-04); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G337S,0.910,Gain of Phosphorylation at G337 (Pr = 0.37 | P = 7.6e-03); Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Methylation at K333 (Pr = 0.25 | P = 2.4e-03); Loss of Acetylation at K333 (Pr = 0.21 | P = 0.03); Loss of SUMOylation at K333 (Pr = 0.19 | P = 0.04), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G609V,0.951,Loss of B-factor (Pr = 0.30 | P = 7.6e-03), None,-
COL4A5_HUMAN,G1241R,0.921,Loss of B-factor (Pr = 0.31 | P = 5.8e-03); Loss of Loop (Pr = 0.29 | P = 9.1e-03); Gain of ADP-ribosylation at G1241 (Pr = 0.21 | P = 0.03); Loss of O-linked glycosylation at S1242 (Pr = 0.16 | P = 0.03); Gain of Methylation at G1241 (Pr = 0.09 | P = 0.05), ELME000006|ELME000135|ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G796V,0.957,Loss of B-factor (Pr = 0.32 | P = 5.2e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Acetylation at K798 (Pr = 0.19 | P = 0.04); Loss of Methylation at K798 (Pr = 0.19 | P = 8.5e-03), None,-
COL4A5_HUMAN,C1638Y,0.950,Altered Metal binding (Pr = 0.65 | P = 1.5e-03); Altered Ordered interface (Pr = 0.41 | P = 6.3e-04); Loss of Disulfide linkage at C1638 (Pr = 0.36 | P = 6.8e-04); Altered Transmembrane protein (Pr = 0.30 | P = 1.3e-04); Gain of Loop (Pr = 0.27 | P = 0.04), ELME000062|ELME000162,-
COL4A5_HUMAN,G923R,0.961,Loss of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K922 (Pr = 0.25 | P = 0.01); Loss of Methylation at K922 (Pr = 0.18 | P = 0.01); Altered Metal binding (Pr = 0.11 | P = 0.04), ELME000100|ELME000108,-
COL4A5_HUMAN,G1448D,0.951,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,P300L,0.392,-,-,-
COL4A5_HUMAN,G1211R,0.951,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.26 | P = 0.05), ELME000155|PS00008,-
COL4A5_HUMAN,G313S,0.940,Altered Disordered interface (Pr = 0.27 | P = 0.05); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1205S,0.934,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of B-factor (Pr = 0.27 | P = 0.02); Loss of Methylation at K1204 (Pr = 0.25 | P = 1.9e-03); Loss of Acetylation at K1204 (Pr = 0.22 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.04 | P = 0.05), ELME000053,-
COL4A5_HUMAN,G672R,0.933,Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000006|ELME000012|ELME000102|ELME000108|ELME000233,-
COL4A5_HUMAN,G1354R,0.953,Loss of Loop (Pr = 0.30 | P = 5.8e-03); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G763R,0.940,Loss of B-factor (Pr = 0.30 | P = 0.01); Loss of Loop (Pr = 0.29 | P = 9.4e-03); Gain of Acetylation at K768 (Pr = 0.28 | P = 4.9e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of SUMOylation at K768 (Pr = 0.19 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000006|ELME000135,-
COL4A5_HUMAN,G1223D,0.953,Gain of Loop (Pr = 0.30 | P = 5.0e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K1222 (Pr = 0.18 | P = 0.01), ELME000002,-
COL4A5_HUMAN,G638D,0.950,Loss of Acetylation at K634 (Pr = 0.28 | P = 5.9e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.4e-03), None,-
COL4A5_HUMAN,G641E,0.930,, ELME000155,-
COL4A5_HUMAN,G911E,0.954,Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S916 (Pr = 0.12 | P = 0.04), None,-
COL4A5_HUMAN,G558D,0.919,Gain of Loop (Pr = 0.27 | P = 0.04); Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of SUMOylation at K560 (Pr = 0.25 | P = 8.8e-03); Loss of Acetylation at K557 (Pr = 0.22 | P = 0.03); Loss of Methylation at K557 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G1140V,0.964,Loss of B-factor (Pr = 0.34 | P = 1.5e-03); Altered Metal binding (Pr = 0.12 | P = 0.03); Gain of O-linked glycosylation at S1136 (Pr = 0.12 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G893V,0.963,Gain of SUMOylation at K895 (Pr = 0.27 | P = 5.0e-03); Loss of Acetylation at K895 (Pr = 0.24 | P = 0.02); Loss of Methylation at K895 (Pr = 0.20 | P = 6.8e-03); Gain of O-linked glycosylation at S889 (Pr = 0.11 | P = 0.05), ELME000064|ELME000220,-
COL4A5_HUMAN,G374A,0.906,Loss of B-factor (Pr = 0.26 | P = 0.05); Gain of SUMOylation at K370 (Pr = 0.25 | P = 9.3e-03); Loss of Acetylation at K370 (Pr = 0.21 | P = 0.03); Loss of Methylation at K370 (Pr = 0.16 | P = 0.01), None,-
COL4A5_HUMAN,G545V,0.946,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Gain of SUMOylation at K544 (Pr = 0.30 | P = 3.3e-03); Gain of Loop (Pr = 0.29 | P = 9.6e-03); Loss of Methylation at K544 (Pr = 0.20 | P = 6.6e-03); Gain of Ubiquitylation at K544 (Pr = 0.16 | P = 0.04); Gain of Proteolytic cleavage at D549 (Pr = 0.13 | P = 0.02), ELME000064|PS00006,-
COL4A5_HUMAN,G567E,0.947,, ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G406D,0.949,Gain of B-factor (Pr = 0.25 | P = 0.03); Loss of Acetylation at K408 (Pr = 0.20 | P = 0.04); Gain of SUMOylation at K408 (Pr = 0.20 | P = 0.04); Loss of Methylation at K408 (Pr = 0.19 | P = 7.6e-03); Gain of Pyrrolidone carboxylic acid at Q407 (Pr = 0.05 | P = 0.03), None,-
COL4A5_HUMAN,G1015V,0.949,Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of B-factor (Pr = 0.27 | P = 0.02), None,-
COL4A5_HUMAN,G400E,0.923,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000155,-
COL4A5_HUMAN,G1205V,0.961,Loss of B-factor (Pr = 0.33 | P = 2.3e-03); Altered Disordered interface (Pr = 0.29 | P = 0.03); Loss of Methylation at K1204 (Pr = 0.27 | P = 1.2e-03); Gain of Acetylation at K1204 (Pr = 0.21 | P = 0.03); Gain of SUMOylation at K1204 (Pr = 0.19 | P = 0.04); Gain of O-linked glycosylation at S1201 (Pr = 0.13 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G896C,0.955,Loss of Acetylation at K895 (Pr = 0.29 | P = 4.9e-03); Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K895 (Pr = 0.26 | P = 6.8e-03); Loss of Methylation at K895 (Pr = 0.21 | P = 5.1e-03), ELME000064|ELME000220|PS00006,-
COL4A5_HUMAN,G802R,0.941,Loss of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of Acetylation at K798 (Pr = 0.23 | P = 0.02); Loss of Methylation at K798 (Pr = 0.19 | P = 8.7e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1360S,0.924,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.26 | P = 0.04); Gain of O-linked glycosylation at S1365 (Pr = 0.17 | P = 0.02), None,-
COL4A5_HUMAN,G183V,0.947,Altered Disordered interface (Pr = 0.29 | P = 0.03); Gain of O-linked glycosylation at T188 (Pr = 0.21 | P = 0.01), ELME000237,-
COL4A5_HUMAN,G213E,0.941,Gain of Loop (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Gain of SUMOylation at K215 (Pr = 0.25 | P = 7.4e-03); Loss of Methylation at K215 (Pr = 0.21 | P = 5.6e-03), None,-
COL4A5_HUMAN,G1412R,0.956,, ELME000012,-
COL4A5_HUMAN,G941D,0.948,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of SUMOylation at K943 (Pr = 0.26 | P = 7.4e-03); Loss of Methylation at K943 (Pr = 0.24 | P = 2.6e-03); Loss of Acetylation at K940 (Pr = 0.22 | P = 0.03), ELME000064,-
COL4A5_HUMAN,G204V,0.956,Loss of B-factor (Pr = 0.31 | P = 5.4e-03); Gain of Loop (Pr = 0.28 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G681D,0.944,Gain of Loop (Pr = 0.30 | P = 6.4e-03); Gain of B-factor (Pr = 0.25 | P = 0.03), None,-
COL4A5_HUMAN,G1433V,0.959,Loss of B-factor (Pr = 0.26 | P = 0.04), ELME000052|PS00008,-
COL4A5_HUMAN,G1036V,0.954,Altered Disordered interface (Pr = 0.31 | P = 0.02), None,-
COL4A5_HUMAN,G740E,0.938,Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G1060E,0.914,Gain of Loop (Pr = 0.30 | P = 5.4e-03); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K1062 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K1062 (Pr = 0.21 | P = 0.03); Loss of Methylation at K1062 (Pr = 0.19 | P = 8.1e-03), ELME000118,-
COL4A5_HUMAN,G573D,0.958,, ELME000155,-
COL4A5_HUMAN,G1205D,0.955,Gain of Loop (Pr = 0.30 | P = 4.6e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Methylation at K1204 (Pr = 0.26 | P = 1.6e-03); Loss of Acetylation at K1204 (Pr = 0.21 | P = 0.03); Altered Metal binding (Pr = 0.11 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q1203 (Pr = 0.05 | P = 0.04), None,-
COL4A5_HUMAN,G644V,0.925,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,G746E,0.943,Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Acetylation at K748 (Pr = 0.19 | P = 0.04); Loss of Methylation at K748 (Pr = 0.19 | P = 8.1e-03), None,-
COL4A5_HUMAN,G273R,0.950,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at R275 (Pr = 0.11 | P = 0.03), ELME000006|ELME000012|ELME000135,-
COL4A5_HUMAN,G1448A,0.920,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000155,-
COL4A5_HUMAN,P324S,0.604,Gain of Phosphorylation at Y320 (Pr = 0.27 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.05); Loss of Sulfation at Y320 (Pr = 0.04 | P = 0.01), ELME000006|ELME000085|ELME000239|ELME000321|PS00005|PS00006,-
COL4A5_HUMAN,I450M,0.105,-,-,-
COL4A5_HUMAN,R777H,0.204,-,-,-
COL4A5_HUMAN,P396L,0.458,-,-,-
COL4A5_HUMAN,L12W,0.536,Altered Signal peptide (Pr = 0.12 | P = 2.2e-03), None,-
COL4A5_HUMAN,L19P,0.863,Gain of Loop (Pr = 0.27 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q22 (Pr = 0.16 | P = 4.1e-03); Altered Signal peptide (Pr = 0.02 | P = 6.8e-03), ELME000136|ELME000159|ELME000336,-
COL4A5_HUMAN,R74Q,0.189,-,-,-
COL4A5_HUMAN,I251T,0.215,-,-,-
COL4A5_HUMAN,E284V,0.057,-,-,-
COL4A5_HUMAN,T336I,0.042,-,-,-
COL4A5_HUMAN,I361M,0.133,-,-,-
COL4A5_HUMAN,A390T,0.037,-,-,-
COL4A5_HUMAN,V392A,0.126,-,-,-
COL4A5_HUMAN,M393V,0.068,-,-,-
COL4A5_HUMAN,P446R,0.284,-,-,-
COL4A5_HUMAN,P453A,0.045,-,-,-
COL4A5_HUMAN,V631A,0.099,-,-,-
COL4A5_HUMAN,I733T,0.100,-,-,-
COL4A5_HUMAN,P747L,0.135,-,-,-
COL4A5_HUMAN,L755V,0.098,-,-,-
COL4A5_HUMAN,A770I,0.126,-,-,-
COL4A5_HUMAN,L791I,0.058,-,-,-
COL4A5_HUMAN,P797S,0.185,-,-,-
